|
|
Education
| 1999-present | University of Arizona, Tucson,
AZ Graduate Program in Public Health |
| 1982-1986 | Rush Medical College, Chicago,
IL Medical Degree |
| 1978-1982 | Knox College, Galesburg, IL Undergraduate Major Chemistry |
Post-Graduate Training:
| 1989-1992 | University of Virginia, Charlottesville,
VA Fellowship- Infectious Disease |
| 1986-1989 | Rush St. Luke's Presbyterian Hospital,
Chicago, IL Residency- Internal Medicine |
Academic Appointments:
| 1992-1996 | Assistant Professor Department of Internal Medicine, University of Virginia |
| 1992-1996 | Clinical Appointment in Infectious Diseases |
HIV/AIDS Research:
Investigator: A Randomized Phase IIIB Comparative Study to Evaluate XXXX TID regimen in Combination with two NRTIs XXXX BID regimen in Combination with two NRTIs versus XXXX BID plus Nelfinavir BID plus a NRTI in HIV-1 Infected Patients.
Investigator: A 24-Week Phase II Multicenter, Randomized, Open-Label Study To Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (XXXX + Indinavir; XXXX+ Zidovudine + Lamivudine; Indinavir + Zidovudine + Lamivudine) In HIV-Infected Patients.
Investigator: A Phase III Randomized, Double-Blinded, Placebo Controlled trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rhu GM-CSF) in Patients with Advanced HIV Disease.
Investigator: Double-Blind Placebo-Controlled Study Comparing The Combination of XXXX Gel with Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infection in Subjects with Acquired Immunodeficiency Syndrome (AIDS).
Investigator: Body Composition and Quality of Life Changes in HIV Infection.
Investigator: A Phase II/III Double-Blind Study of the Safety and Antiviral Activity of XXXX with Interferon a-2B Compared to Interferon a-2B Alone for the Treatment of Patients with Hepatitis C and Co-Infected with HIV.
Investigator: A Phase III Trial to Determine the Efficacy of Bivalent XXXX in Adults at Risk of Sexually transmitted HIV-1 Infection in North America.
Investigator: a randomized, Double-blind, Placebo-controlled Study of XXXX in Combination with VIRACEPTTM (nelfinavir mesylate) and Combivir TM (zidovudine + lamivudine) in Treatment-naïve HIV-infected Patients.
Investigator: A Phase II, Open-Label Study of Efavirenz in Combination with Protease Inhibitors and 2 Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients who have Experienced Virologic Failure in Study XXXX or XXXX.
Investigator: A Multicenter, Double-Blind, Randomized,
Placebo-Controlled Evaluation of XXXX in Adult Subjects with HIV-Associated
Peripheral Neuropthy.
